



Discovery Fueled by Ultra-Sensitivity

## Quanterix to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 2, 2025

BILLERICA, Mass.--(BUSINESS WIRE)--Jan. 2, 2025-- [Quanterix Corporation](#) (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the 43<sup>rd</sup> Annual J.P. Morgan Healthcare Conference taking place January 13<sup>th</sup>-16<sup>th</sup> at the Westin St. Francis Hotel in San Francisco, CA. Quanterix's presentation will be on Wednesday, January 15, 2025, at 4:30 p.m., PST. In addition to the session, Quanterix will also host one-on-one meetings with institutional investors during the conference.

### Webcast Information

The live webcast presentation can be accessed from the [Investors](#) section of the company's website at [www.quanterix.com](http://www.quanterix.com). A replay of the webcast will be available for a limited period following the conference.

To learn more about Quanterix, visit [www.quanterix.com/company](http://www.quanterix.com/company). To learn more about Quanterix's Simoa® technology, visit [www.quanterix.com/simoa-technology](http://www.quanterix.com/simoa-technology).

### About Quanterix

From discovery to diagnostics, Quanterix's ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,100 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at <https://www.quanterix.com> or follow us on [Twitter](#) and [LinkedIn](#).

### Forward-Looking Statements

*This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.*

View source version on [businesswire.com](http://businesswire.com): <https://www.businesswire.com/news/home/20250102680151/en/>

### Media Contact:

Marissa Klaassen  
[media@quanterix.com](mailto:media@quanterix.com)

### Investor Relations Contact:

Joshua Young  
[ir@quanterix.com](mailto:ir@quanterix.com)

Source: Quanterix Corporation